title: Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes.
abstract: BACKGROUND
  Diffuse field change with actinic keratoses (AK) is a ubiquitous skin disease in Australia, with potential for malignant transformation. We report on 35 consecutive patients who had field therapy with single session photodynamic therapy (PDT) using 1 h incubation time for 5-aminolevulinic acid (5-ALA) or 3 h for methyl-aminolevulinate (MAL).
  
  
  METHODS
  We retrospectively telephone surveyed our patient cohort regarding their satisfaction and perceptions of the effectiveness, side-effect profile and benefits of PDT. We also reviewed all patients' notes for significant side-effects.
  
  
  RESULTS
  Sixty-nine per cent (n = 24/35) of patients responded to the telephone survey; 66% (n = 16/24) of the respondents reported good clearance of AK and claimed a good cosmetic outcome. All respondents reported moderate or severe pain (42% and 58%, respectively) during the illumination phase. Twenty per cent of all patients treated had suffered from one or more of the following side-effects: pustulation; severe erythema; and skin erosions.
  
  
  CONCLUSIONS
  Overall, our results compared favourably with previously published studies using 5-ALA or MAL PDT. However, our patient cohort experienced a greater side-effect profile. This may have been due to our patients having greater disease burden compared to other studies and possibly due to our use of topical retinoids prior to PDT in selected patients.
authors.affiliation: Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales, Australia. drdtt@hotmail.com
authors.forename: Dai T
authors.initials: DT
authors.lastname: Tran
authors.forename: Robert
authors.initials: R
authors.lastname: Salmon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000622:Aminolevulinic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000188:drug therapy*; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D008875:Middle Aged; D017060:Patient Satisfaction; D010778:Photochemotherapy / Q000009:adverse effects; D017319:Photosensitizing Agents / Q000627:therapeutic use; D012536:Scalp Dermatoses / Q000188:drug therapy*
chemical_list: D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid